Medicine and Dentistry
Anal Sphincterotomy
9%
Biological Marker
48%
Chemoradiotherapy
8%
Chronic Pancreatitis
22%
Collagen Degradation
14%
Collagen Type 1
14%
Collagen Type 4
18%
Combination Therapy
9%
Computer Assisted Tomography
14%
Conservative Treatment
11%
Crohn's Disease
47%
Diagnosis
11%
Disease
44%
Disease Activity
21%
Distant Metastasis
9%
Endoscopic Retrograde Cholangiopancreatography
13%
Endoscopic Ultrasound
70%
Esophageal Cancer
67%
Esophagus
10%
Esophagus Carcinoma
13%
Extracellular Matrix
20%
False Positive Result
10%
Fine-Needle Aspiration
11%
Fluorodeoxyglucose
12%
Fluorodeoxyglucose F 18
10%
Gut Microbiota
8%
Health Care Cost
11%
Inflammatory Bowel Disease
81%
Infliximab
23%
Magnetic Resonance Imaging
15%
Neoplasm
18%
Neutrophil
11%
Pancreas Cancer
8%
Pancreatic Cysts
11%
Pancreatitis
20%
Patient with Crohn's Disease
27%
Patient with Inflammatory Bowel Disease
20%
Positron Emission Tomography
25%
Positron Emission Tomography
20%
Proteomics
8%
Pylorus Stenosis
8%
Quality of Life
16%
Randomized Controlled Trial
13%
Surgery
13%
Symptom
9%
Symptomatic Treatment
10%
Treatment Response
14%
Tumor Necrosis Factor
16%
Ulcerative Colitis
21%
Vedolizumab
15%
Immunology and Microbiology
Antibody Blood Level
9%
Antibody Response
6%
Antiinflammatory Activity
5%
Azathioprine
9%
Bacteriophage
8%
C-Reactive Protein
6%
Colitis
7%
Collagen Degradation
12%
Colon
6%
Computer Assisted Tomography
5%
Crohn's Disease
73%
Enteritis
6%
Epitope
15%
Extracellular Matrix
20%
Immunoprecipitation
13%
Inflammatory Bowel Disease
100%
Infliximab
21%
Intestine Flora
7%
Microflora
12%
Multidrug Resistance Protein 1
5%
Neutrophil
14%
Pancreatitis
8%
Prevalence
5%
TLR4
5%
Tumor Necrosis Factor
15%
Ulcerative Colitis
27%
Vedolizumab
15%
Keyphrases
Antibody Epitope
8%
Antibody Signature
5%
Biological Therapy
5%
Clinical Phenotype
9%
Co-immunoprecipitation (co-IP)
8%
Collagen Degradation
7%
Crohn's Disease
28%
Disease Activity
11%
Disease Location
5%
Endoscopic Disease Activity
8%
Fecal Calprotectin
7%
Gut Microbiota
5%
Gut Microbiota Composition
5%
Host-microbe Interactions
8%
Induction Therapy
8%
Inflammation
6%
Inflammatory Bowel Disease
70%
Infliximab
13%
Intestinal Failure
5%
Intestinal Transplantation
8%
Microbial Composition
5%
Mucosal Inflammation
5%
Serum Biomarkers
5%
Specific Antibodies
5%
Staged Strategy
5%
Transcriptional Network
5%
Type I Collagen
10%
Type III Collagen
6%
Ulcerative Colitis
11%
